Study of ZG005 in Patients With Advanced Solid Tumors
Interventionnel
Phase 2
Sun Yat-sen University Cancer Center
Sponsor: Zelgen Biopharmaceuticals
Dernière synchronisation : 5 janvier 2026 Avis - Les informations proviennent de registres publics et peuvent ne pas refléter les changements en temps réel sur le site local.
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
* Fully understand the study and voluntarily sign the informed consent form.
* Male or female 18-75 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1;
* Life expectancy ≥ 12 weeks;
* Histologically or cytologically confirmed diagnosis of advanced solid tumors.
Critères d'exclusion
* Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
* Any other malignancy within 5 years.
Pensez-vous que cet essai apparaît incorrectement ?
Détails de la conception
AllocationN/A
Modèle d'interventionSingle Group Assignment
MasquageNone (Open Label)
Nombre à inscrire100
Bras et interventions
Bras
Interventions
Type : Experimental
Description : ZG005 dose expansion was performed in different tumors, such as: nasopharyngeal carcinoma, esophageal squamous cell carcinoma, and other carcinoma
Interventions :
ZG005 for Injection
Mesures des résultats
Mesures des résultats primaires
Objective response rate(ORR)Up to 2 years
Mesures des résultats secondaires
Adverse Event (AE)Up to 2 years
Mettre l'essai en favori
Partager l'essai
Télécharger l'essai
Pensez-vous que cet essai apparaît incorrectement ?